>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<1.0 EU per 1 μg of the protein by the LAL method.
Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is >3,900 pmol/min/µg as measured under the described conditions. See Activity Assay Protocol on www.RnDSystems.com.
Mouse myeloma cell line, NS0-derived Asn29-Pro766, with a C-terminal Asp-Ile and 6-His tag
Recombinant Human DPPIV/CD26 (Catalog # 9168-SE) is measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The activity (orange) is approximately 4-fold greater than the competitor's DPPIV/CD26 (green).
DPPIV/CD26 (EC 18.104.22.168) is an approximately 110 kDa serine exopeptidase that releases Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of oligo- and polypeptides. It regulates immune and endocrine function through the cleavage of multiple chemokines, growth factors, and peptide hormones (1, 2). Mature human DPPIV consists of a 6 amino acid (aa) cytoplasmic tail, a 22 aa transmembrane segment, and a 738 aa extracellular domain (ECD) that contains the catalytic active site (Ser, Asp, and His charge relay system) (3). Within the ECD, human DPPIV/CD26 shares 84% amino acid sequence identity with mouse and rat DPPIV. DPPIV is expressed as a noncovalent homodimer on the surface of epithelial cells, endothelial cells, and activated lymphocytes, and it can be released by MMP mediated shedding (4). It cleaves a range of peptide hormones including Glucagon, Glucagon-like Peptides 1 and 2, GIP, GHRH, Procalcitonin, Neuropeptide Y, and Substance P (5). It is released from adipocytes and induces insulin resistance in adipocytes and skeletal muscle (6). DPPIV also cleaves many chemokines, resulting in reduced chemotactic activity of CXCL6, 9, 10, 11, 12, and CCL5 (7-10) but unchanged angiostatic activity of CXCL9 and CXCL10 (8). Cleavage can increase (CCL5), decrease (CXCL12), or have no effect (CCL4) on chemokine blockade of HIV-1 cellular infectivity (7, 9, 11). In addition, DPPIV cleavage of CCL4 broadens chemokine receptor usage to also include CCR2b (11). DPPIV serves as a cell entry coreceptor for HIV and coronavirus (12, 13). It cleaves human GM-CSF and IL-3 and reduces their ability to promote myeloid cell development (14). It also interferes with CXCL12 induced hematopoietic cell migration, homing, and engraftment (15). DPPIV interacts in cis with adenosine deaminase on T cells and in trans with caveolin-1 on antigen presenting cells (16, 17). It provides costimulatory proliferation and activation signals to both CD4+ and CD8+ T cells (17, 18).
Klemann, C. et al. (2016) Clin. Exp. Immunol. Epub PMID 26919392.
Mortier, A. et al. (2016) J. Leukoc. Biol. Epub PMID 26744452.
Tanaka, T. et al. (1992) J. Immunol. 149:481.
Rohrborn, D. et al. (2014) FEBS Lett. 588:3870.
Waumans, Y. et al. (2015) Front. Immunol. 6:387.
Lamers, D. et al. (2011) Diabetes 60:1917.
Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
Proost, P. et al. (2001) Blood 98:3554.
Ohtsuki, T. et al. (1998) FEBS Lett. 431:236.
Barreira da Silva, R. et al. (2015) Nat. Immunol. 16:850.
Guan, E. et al. (2002) J. Biol. Chem. 277:32348.
Callebaut, C. et al. (1993) Science 262:2045.
Raj, V.S. et al. (2013) Nature 495:251.
Broxmeyer, H.E. et al. (2012) Nat. Med. 18:1786.
Christopherson II, K.W. et al. (2004) Science 305:1000.
Kameoka, J. et al. (1993) Science 261:466.
Ohnuma, K. et al. (2007) J. Biol. Chem. 282:10117.